Stock Watch: Digging Holes And Clutching At Straws In Biotech R&D
Tenacity Is Not Always A Virtue
Biotech CEOs often express surprise when the FDA rejects their drugs. But collaborative interactions between regulators and drug sponsors count for little if the latter fail to adjust their clinical and regulatory efforts accordingly.
